@article{mbs:/content/journal/acmi/10.1099/acmi.0.000052, author = "Huang, D. B. and Noviello, S. and Gemmell, C. G.", title = "Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model", journal= "Access Microbiology", year = "2019", volume = "1", number = "7", pages = "", doi = "https://doi.org/10.1099/acmi.0.000052", url = "https://www.microbiologyresearch.org/content/journal/acmi/10.1099/acmi.0.000052", publisher = "Microbiology Society", issn = "2516-8290", type = "Journal Article", keywords = "iclaprim", keywords = "murine model", keywords = "septic arthritis", eid = "e000052", abstract = " Staphylococcus aureus is the most common non-gonococcal aetiology of septic arthritis. The efficacy of iclaprim against S. aureus LS-1, a clinical strain identified from a patient with septic arthritis, was studied in MF1 mice to evaluate the activity of iclaprim, which is in clinical development, in preventing joint infections. Iclaprim (2.5–80 mg kg− 1) administered as a single dose via the tail vein reduced the incidence of S. aureus septic arthritis and mortality in an experimental murine model of septic arthritis.", }